Cellular Biomedicine Group Completes Patient Treatment in Phase IIb Clinical Trial for ReJoin(TM) Therapy for Knee

Cellular Biomedicine Group Completes Patient Treatment in Phase IIb Clinical
Trial for ReJoin(TM) Therapy for Knee Osteoarthritis

PALO ALTO, Calif., Aug. 12, 2014 (GLOBE NEWSWIRE) -- Cellular Biomedicine
Group Inc. (Nasdaq:CBMG) (the "Company") today announced that it has treated
the final patient in its Phase IIb trial to further evaluate the safety and
efficacy of their proprietary adipose-derived mesenchymal precursor cell
(haMPC)-based therapy ReJoin^TM for Knee Osteoarthritis (KOA).

Dr. William (Wei) Cao, Chief Executive Officer of the Company, commented, "The
patient enrollment and treatment were carried out smoothly and completed
earlier than anticipated. There have been no Severe Adverse Events (SAE)
observed to date. We are very pleased with the progress of ReJoin^TMtherapy
Phase IIb trial. The excellent readout from the six-month follow-up of the
Phase I/IIa trial makes us optimistic about theresults of the Phase IIb
trial, which will be announced in the first quarter of 2015." A Phase I/IIa
twelve-month follow-up MRI readout has been completed and we expect the
official report to be available by early fourth quarter of 2014.

Full data analysis will be carried out by FuDan Medical University Department
of Biostatistics, one of the most authoritative biostatistics institutions in
China.

The Phase I/IIa clinical trial for this therapy was completed in the fourth
quarter of 2013, with the six-month follow-up data analysis concluding that
ReJoin^TM cell therapy for KOA patients is safe and revealing an increase in
cartilage volume as early as three months after the therapy. (click here to
view detailed six-month data).

About the Clinical Trial

The Phase IIb clinical research trial for KOA, registered with the U.S.
National Institutes of Health (NIH) under the number NCT02162693 (click here
to view), is led by Shanghai Renji Hospital, one of the largest teaching
hospitals in China. The multi-center study enrolled 53 patients to participate
in a randomized, single-blind trial.

The primary endpoints for this trial are knee-related pain, stiffness and
function as measured using the Western Ontario and McMaster Universities
(WOMAC) osteoarthritis index questionnaire. The secondary endpoints are
cartilage repair at six months by assessment of changes of the knee joint
cartilage's volume measured with quantitative magnetic resonance imaging
(MRI), in addition to NRS-11, SF-36 and KSCRS scores, and the recording of any
moderate to serious adverse events.

About Cellular Biomedicine Group

Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the
treatment of certain degenerative diseases and cancers. Our developmental
stem cell, progenitor cell, and immune cell projects are the result of
research and development by scientists and doctors fromChinaandthe United
States. Our flagship GMP facility, consisting of eight independent cell
production lines, is designed, certified and managed according to U.S.
standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com

Forward-Looking Statements

Statements in this press release relating to plans, strategies, trends,
specific activities or investments, and other statements that are not
descriptions of historical facts may be forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, Section 27A
of the Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended. Forward-looking information is inherently
subject to risks and uncertainties, and actual results could differ materially
from those currently anticipated due to a number of factors, which include,
but are not limited to, risk factors inherent in doing business.
Forward-looking statements may be identified by terms such as "may," "will,"
"expects," "plans," "intends," "estimates," "potential," or "continue," or
similar terms or the negative of these terms. Although CBMG believes the
expectations reflected in the forward-looking statements are reasonable, they
cannot guarantee that future results, levels of activity, performance or
achievements will be obtained. CBMG does not have any obligation to update
these forward-looking statements other than as required by law.

CONTACT: Sarah Kelly
         Director of Corporate Communications, CBMG
         +1 650 566-5064
         sarah.kelly@cellbiomedgroup.com
        
         Vivian Chen
         Managing Director Investor Relations, Grayling
         +1 646 284-9427
         vivian.chen@grayling.com

Cellular Biomedicine Group Inc. Logo
 
Press spacebar to pause and continue. Press esc to stop.